

NORTH
MACEDONIA

VHPB BALKAN MEETING

*CURRENT SITUATION:
EPIDEMIOLOGY, BURDEN OF
DISEASE, SCREENING &
PREVENTION, CASCADE OF
CARE*

Marija Dimzova MD PhD

University clinic for infectious diseases and febrile conditions
medical faculty, Uni Ss Cyril and Methodius-Skopje



COUNTRY NORTH MACEDONIA

EPIDEMIOLOGY

	HBsAg (2021)	Anti-HCV (2021)
General population	1,4 /100 000	NA
Blood donors (first time)	88/12953 (0.68%)	5/12953 (0.0038%)
Pregnant women	NA	NA
Risk Groups	NA	NA
PWID	NA	NA
MSM	NA	NA
Prisoners	NA	NA
Other	NA	NA
Healthcare workers	NA	NA

	In risk-population (specify)	Prevalence (2020)
Anti HAV	NA	2,6
Anti HEV	NA	NA

COUNTRY EPIDEMIOLOGY

NORTH MACEDONIA

Data from report cards of infectious diseases¹

Year	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
Acute hepatitis B	215	193	165	153	154	184	165	171	148	104	72	88	91	37	29	22
MB/100.000 HBV	10.5	9.5	8.1	7.5	7.5	9.0	8.0	8.3	7.2	5.0	3.5	4.3	4.4	1.8	1.4	
Acute hepatitis C	111	99	83	72	76	166	70	63	60	45	29	35	50	10	3	10
MB/100.000 HCV	5.4	4.9	4.1	3.5	3.7	8.1	3.4	3.0	2.9	2.2	1.4	1.7	2.4	0.5	0.1	
HBSAg + carrier state	55	26	37	71	50	86	158	91	78	62	49	40	37	18	12	6
HCV carrier state	/	/	/	41	64	66	38	29	27	22	24	6	39	12	7	2
Chronic hepatitis B	/	/	/	2	10	23	30	32	31	15	39	28	14	5	5	/
Chronic hepatitis C	22	13	10	11	16	9	18	14	27	13	39	42	13	2	7	/
Acute hepatitis A	257	243	290	310	303	189	101	582	157	20	36	72	215	54	4	7
MB/100.000 HAV	12.6	11.9	14.2	15.2	14.7	9.2	4.9	28.2	7.6	1.0	1.7	3.5	10.4	2.6	0.2	

Data from isolate reports¹

Year	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
Hepatitis A	30	49	23	513	95	12	33	54	203	56	3	7
Hepatitis B	21	131	85	86	71	81	65	68	60	42	50	98
Hepatitis C	33	156	137	155	211	523	332	379	407	122	89	87
Carrier state HBSAg+	28	49	126	194	286	290	326	291	417	210	267	116

¹ Data from the State Institute for Public Health



COUNTRY EPIDEMIOLOGY

NORTH MACEDONIA

Prevalence of transfusion-transmissible infections in blood donors¹

Period	Tested donors No	Prevalence of HBV, HCV and HIV		First time donors		Multiple donors	
		No	%	No	%	No	%
2017-2019	75763	174	(0.23%)	164	(0.32%)	10	(0.038%)
2020	21342	84	(0.39%)	80	(0.66%)	4	(0.042%)
2021	24169	102	(0.42%)	94	(0.72%)	8	(0.061%)

HBV and HCV prevalence in blood donors¹

Period	Tested donors No	Prevalence of HBV		Prevalence of HCV	
		No	%	No	%
2017-2019	75763	151	(0.020)	18	(0.023)
2020	21342	77	(0.36)	4	(0.018)
2021	24169	93	(0.38)	5	(0.020)

HBV and HCV prevalence in first time blood donors¹

Period	Tested donors		Prevalence of HBV		Prevalence of HCV	
	No	%	No	%	No	%
2017-2019	49711		147	(0.30)	15	(0.03)
2020	1200		74	(0.61)	4	(0.033)
2021	12953		88	(0.68)	5	(0.038)

¹Data from the State Institute for Transfusion Medicine

COUNTRY NORTH MACEDONIA

VACCINATION PROGRAM

Hepatitis A	Y/N	population + Schedule	Since/period
Universal	No	Not available	
Risk group	YES	HCW, public hygiene and sewage workers , daycare centers, education, long term facilities- recommended	

Hepatitis B	Y/N	population + Schedule	Since/period
Universal	Yes	At birth 0,2 and 6 months	2004/ 91.3% scope
Catch-up	YES	At the latest of the start of primary education (5 years) 0,1 and 6 months	2004
Risk Group	Yes	Medical workers, pts with hemophilia, HD pts, partners of HBsAg positive persons, residents of institutions for social protection, PWID, HCV positive, HIV/AIDS, people with STD and partners, PEP 0,1 and 6m + HBIG	

COUNTRY NORTH MACEDONIA

SCREENING

Recommended for following groups:	Hep B	Hep C
General population	No	No
Birth cohorts	Yes	Yes
Blood and organ donors	Yes	Yes
Pregnant women	Yes	Yes
PWID	Yes	Yes
STI clinic patients	Yes	Yes
Haemodialysis patients	Yes	Yes
Health care workers	Yes	No
Men having sex with men	Yes	Yes
Prison population	Y/N-2025	Y/N-2025
Migrants	No	No
Others		

COUNTRY NORTH MACEDONIA

TREATMENT

National guidelines available	Y/N (year)
Hepatitis B	Yes 2004
Hepatitis C	Yes 2004
Other (specify) HIV	Yes 2003

COUNTRY NORTH MACEDONIA

TREATMENT

Drugs available for HCV treatment*	Y/N
PegInterferon	No
Ribavirin	No
Boceprevir	No
Telaprevir	No
Simeprevir	No
Sofosbuvir	No
Daclatasvir	No
Sofosbuvir/Ledipasvir	No
Sofosbuvir/Velpatasvir	Yes
Glecaprevir/Pibrentasvir	Yes
Sofosbuvir/Velpatasvir/Voxilaprevir	No
Other (specify)	

Drugs available for HBV treatment*	Y/N
Lamivudine	Yes
Adefovir	No
Telbivudine	No
Entacavir	No
TDF	No
TAF	No

Number of patients treated (cumulative)

Hep B	534±50 annually
Hep C	PEG-IFN 459 + / DAAs 259

*included on the national essential medicines list or subsidized by the government

